Biotechnology

Thursday Jul 28, 2022 - 9:00 am

Pro Athletes Provide Specialized Advocacy for Odyssey Health, Inc.’s (ODYY) Solution for Concussion-related Brain Injuries

CDC estimates put the incidence of athlete concussion incidents at 5 to 10 percent of playersCurrently, there is no FDA-approved medicinal treatment for helping people with concussion injuriesOdyssey Health Inc. is a company developing a drug-device combination to treat concussion patients in the first minutes after injuryRetired pro soccer and football athletes Abby Wambach, Kurt Warner, and Brett Favre, have formed a Sports Advisory Board…

Tuesday Jul 26, 2022 - 9:00 am

Odyssey Health, Inc. (ODYY), Determined to Introduce the Market’s First FDA Approved Concussion Treatment Drug

PBS News Hour estimates that, for college students, concussions cost between $446 million and $1.5 billion annually, while for high school students the cost ranges from $5.4 billion to $19.2 billionOdyssey, through its flagship product, PRV-002, hopes to offer the first FDA-approved drug treatment for concussionsOnce approved, Odyssey is confident that PRV-002 will bring relief to thousands of victims, reduce the cost of concussion treatment…

Monday Jul 25, 2022 - 11:15 am

Silo Pharma Inc. (SILO) Produced Initial Liposome Batch for Rheumatoid Arthritis Study

Silo Pharma produced initial batch of SPU-21 liposomes for rheumatoid arthritis study conducted by CRO Frontage LaboratoriesRecent company research revealed SPU-21 liposomes can target inflamed epithelium, suggesting use for targeted drug deliverySPU-21 can be used for development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis Company recently announced positive results in subcutaneous delivery of novel liposomes vs. intravenous injection Silo Pharma (OTCQB: SILO), a…

Monday Jul 25, 2022 - 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Completes Acquisition of Largest-Ever DMT Study

Data from newly acquired study could accelerate clinical development of CYBN’s CYB004 by nine monthsThe pivotal study was designed with four primary objectivesCybin’s proprietary substance has potential to effectively treat anxiety disorders, including GAD and SAD Cybin (NEO: CYBN) (NYSE American: CYBN) has completed the acquisition of the largest dimethyltryptamine (“DMT”) study to date, a Phase 1 N,N-DMT study that provides key data relating to the…

Friday Jul 22, 2022 - 9:00 am

Successful Early Testing of Concussion Therapy Drives Optimism for Odyssey Health, Inc. (ODYY) as Next-stage Trials are Readied

Medical technology innovator Odyssey Health Inc. is using clinical tests to establish the safety of a therapy designed to treat concussion injuries in its earliest moments The company is enthused by results from the early-stage testing and is preparing to design a Phase II/III trial that will target efficacy results in volunteer subjects, focusing particularly on members of the military Odyssey’s technology combines a synthetic medication with…

Wednesday Jul 20, 2022 - 9:00 am

Odyssey Health, Inc. (ODYY) Responds to Growing Concerns About Concussion Head Injuries with Drug Device in Clinical Trial

As awareness of the long-term hazards of concussive head injuries for young athletes has increased during the past decade, advocates and business enterprises have stepped up to improve coach responsiveness to players’ conditionWhile efforts primarily focus on assessing injury, Odyssey Health Inc. is developing a product it hopes to become the first drug device with FDA approval for treating a concussed patient after injuryOdyssey is…

Tuesday Jul 19, 2022 - 9:45 am

QSAM Biosciences Inc. (QSAM) Marks Milestone with Dosing of First Patient in CycloSam Clinical Trial

Treating patients with primary or secondary bone cancer remains goal, says company CEORadiopharmaceuticals is a new class of drugs that delivers radiation therapy directly to cancer cellsQSAM is working to develop CycloSam(R) as a breakthrough therapeutic for adult and pediatric bone cancer patients QSAM Biosciences (OTCQB: QSAM), a company developing a new class of drugs called radiopharmaceuticals, is leading the charge to evaluate a new treatment…

Wednesday Jul 13, 2022 - 9:00 am

Homing Peptides: Silo Pharma Inc. (SILO) Targets ADRs

Silo’s partnership with UMB could yield therapeutics that limit side effects through precisely targeted delivery On February 3, 2022, Silo Pharma (OTCQB: SILO) extended its research partnership with the University of Maryland, Baltimore (“UMB”) to explore potentially lifesaving joint-homing peptides that target inflamed endothelium (a thin membrane that lines the inside of the heart and blood vessels). The ability to target inflamed tissue (while bypassing…

Monday Jul 11, 2022 - 12:00 pm

Odyssey Health, Inc.’s (ODYY) Sports Advisory Board Enhancing Public Awareness and Understanding of Traumatic Brain Injuries

Odyssey’s Sports Advisory Board (“SAB”) was formed in 2021 to enhance public awareness of traumatic brain injuries and concussionThe board’s members – Abby Wambach, Kurt Warner, and Brett Favre – have had storied careers in their respective sports and have expressed hope that scientists will examine their brains after their death to advance their understanding of head traumaAbby Wambach has committed her brain to research,…

Wednesday Jul 06, 2022 - 11:15 am

Odyssey Health, Inc. (ODYY) Optimistic About Drug/Tech IP as Industry Studies Big Pharma M&A Outlook

Biopharma industry analysts have been expecting 2022 to be a heady year for big-pharma acquisitions or partnerships with promising medical upstarts following a time period that has left the biggest companies flush with cashAmong promising device and drug developers, Odyssey Health Inc. has been working on novel solutions to brain concussion injuries, a rare neurodegenerative disease, obstructive choking incidents and early-stage coronary artery disease (“CAD”)…

Friday Jul 01, 2022 - 9:00 am

Odyssey Health, Inc. (ODYY) Reports Positive Findings on Phase 1 Clinical Trials of PRV-002 for Concussions

No adverse reactions were reported in any of the healthy subjects enrolled in the Cohort II Phase 1 clinical trial of PRV-002 Company in talks with military training sites for Phase 2 and 3 clinical trials on concussed patientsThe CDC estimates that approximately 1.6 to 3.8 million sports and recreation-related concussions occur annually, for which there is no FDA-approved treatmentThe global concussion market size was valued…

Wednesday Jun 29, 2022 - 10:30 am

Odyssey Health, Inc. (ODYY) Taps Military Advisors to Address Target Market for PRV-002 Concussion Drug

Odyssey Health is a medical company focused on developing medical products for conditions with unmet needs, one of which is concussionCurrently, concussions do not have an FDA-approved treatmentSoldiers form a significant population of people who frequently experience multiple concussions throughout their careerConcussion has only recently received greater attention as different parties seek to understand the condition and possible treatmentsOdyssey is at the forefront of this…

Tuesday Jun 28, 2022 - 11:15 am

Aditxt Inc. (NASDAQ: ADTX) Authorizes New Channel Partner to Offer AditxtScore(TM) Amid Rising COVID-19 Cases and Possible Fall/Winter Waves

Aditxt, Inc. is a is a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system. The Company’s product AditxtScore(TM) is a proprietary immune mapping technology designed to provide a personalized profile of the immune system; AditxtScore(TM) for COVID-19 is the Aditxt’s first commercial productAditxt recently announced it had authorized a new channel partner – Premier Medical Laboratory Services (“PMLS”),…

Monday Jun 27, 2022 - 2:15 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports Initial Results from Feasibility Study

Study indicates that ketamine-induced changes in functional connectivity last for several days after administration of the substanceKernel Flow gathers real-time functional brain activity during clinical and research studies evaluating psychedelic-based therapeuticsTechnology is “precisely what we need to accelerate the development of psychedelics into therapeutics,” says Cybin CEO New data confirms Cybin’s (NEO: CYBN) (NYSE American: CYBN) focus on and commitment to progressing psychedelics to therapeutics. The…

Monday Jun 27, 2022 - 1:30 pm

Silo Pharma Inc. (SILO) Takes Aim at Alzheimer’s Disease

In October 2021, Silo Pharma (OTCQB: SILO) entered into a sponsored research agreement (“SRA”) with Columbia University to investigate and advance psychedelic therapeutics for Alzheimer's Disease (“AD”). SRA’s grant Silo access to world-class research facilities to sponsor potential life-changing research while offering Silo licensing opportunities for groundbreaking psychedelic remedies. Columbia University Irving Medical Center (“CUIMC”), an “internationally recognized leader” in research and therapeutic development, partnered…

Monday Jun 27, 2022 - 9:45 am

Odyssey Health, Inc. (ODYY) Targeting Achievement of Important Milestones, as It Progresses Clinical Trials of Novel Concussion Drug

Odyssey Health is focused on developing life-saving medical products and pharmaceutical assets that offer a technological and clinical advantageThe company is developing the CardioMap Heart Monitoring and Screening Device and the Save-a-Life choking rescue device Its drug-device combination is intended to get PRV-002, Odyssey’s novel treatment for concussion, to the brain rapidly after concussionIn an interview with RedChip Companies CEO Dave Gentry, Odyssey CEO Michael Redmond…

Friday Jun 24, 2022 - 12:00 pm

Hope of Herd Immunity Dwindles Alongside Federal COVID-19 Budget and Supplies; Aditxt Inc. (NASDAQ: ADTX) and AditxtScore(TM) Could Create Map to COVID-19 Immune Responses

Two years after a vaccine was made available for COVID-19, fewer than 70% of Americans have been vaccinatedThe AditxtScore(TM) can provide the necessary answers to individualized immune response questions and direct on the best course of treatment for the individual – not the herdNo additional funding for COVID-19 relief has been approved by Congress, requiring the Biden Administration to reallocate funds to prepare for the…

Tuesday Jun 14, 2022 - 11:15 am

Odyssey Health, Inc. (ODYY) Moving to Fill Gaps in Treatment and Management of Concussion Among Military Service Members

Odyssey is a medical company developing PRV-002, a novel compound for the treatment of concussionBetween 75-83% of all the cases of traumatic brain injury (“TBI”) among U.S. service members have been classified as mild (“mTBI”), commonly termed “concussion”Although concussion greatly impacts the military, there are significant gaps in the understanding of the optimal diagnostic, treatment, and management criteriaOdyssey is looking to bridge this informational gap…

Tuesday Jun 14, 2022 - 9:00 am

Aditxt Inc.’s (NASDAQ: ADTX) AditxtScore(TM) Platform Provides Consumers and Physicians with Data Needed to Make Informed Health Decisions on COVID-19

Aditxt is a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system.The company’s AditxtScore(TM) for COVID-19 generates an AditxtScore(TM), which offers a detailed profile of a person’s immune response for SARS-CoV-2, allowing consumers and their physicians to understand, manage, and monitor their level of immune response to the virus, thus allowing them to make informed health decisionsAditxt’s platform is…

Friday Jun 10, 2022 - 9:00 am

New Spike in COVID Infections, 1M+ Death Toll, Underscore Potential Value of Aditxt Inc.’s (NASDAQ: ADTX) Immune Monitoring Technologies

Biotech innovation company Aditxt, Inc. is a Richmond, VA based company focused on developing and commercializing technologies to monitor and reprogram the immune system with the ultimate goal of improving patient outcomes for a variety of conditions ranging from seasonal allergies to organ transplant rejectionAditxt’s first commercial product, AditxtScore(TM), helps patients obtain data relating to COVID-19 infection and vulnerabilityWhile immunization rates and the seasonal reduction…

Wednesday Jun 08, 2022 - 10:30 am

Odyssey Health, Inc. (ODYY) Marks New Milestone in Pursuit of Concussion Treatment with Positive Safety Findings from Cohort I of Phase 1 Clinical Trial for PRV-002

Odyssey Health is a medical company focused on unique, life-saving medical products that offer clinical advantages to conditions with unmet needsThe subject of an ongoing Phase I clinical trial, Odyssey’s PRV-002 is a novel compound for treating concussion, which currently has no FDA-approved drugData from Cohort I of the Phase I study showed that PRV-002 is well-tolerated, with no adverse events being observedThe company believes…

Tuesday May 31, 2022 - 11:15 am

Silo Pharma Inc. (SILO) Focuses on Psilocybin’s Anti-Inflammatory Properties

On May 19, 2022, Silo Pharma (OTCQB: SILO) announced that The Translational Psychedelic Research (“TrPR”) Program at UCSF (University of California San Francisco) had “successfully dosed [with psilocybin] patients suffering from Parkinson’s disease.” TrPR connects researchers and medical professionals studying how psychedelics, including psilocybin, ketamine, etc., affect brain functions and other organ systems. Silo Pharma focuses on palliative uses of psychedelics for “PTSD, Parkinson’s, and…

Tuesday May 31, 2022 - 9:45 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) and Kernel Report Result of Study Measuring Ketamine’s Effects on the Brain

Study shows that COVID-19 pandemic has affected mental health of 59% of U.S. population, intensifying already-serious issueCYBN-sponsored feasibility study indicates ketamine-induced changes in brain’s functional connectivity persisted for several days after receiving the substanceKernel Flow pivotal in developing most accurate, effective treatment regimens for patients The challenges associated with mental-health issues are rising, following the global pandemic. Already a serious problem before COVID-19, mental health…

Tuesday May 31, 2022 - 9:00 am

Odyssey Group International Inc. (ODYY) Is ‘One to Watch’

Odyssey boasts a diverse development portfolio spanning both pharmaceutical candidates and medical devicesThe company is evaluating PRV-002 for the treatment of concussion, a dramatically underserved indication that currently has no FDA-approved drugWith PRV-001, Odyssey aims to receive Orphan Drug designation, which could potentially accelerate its pathway to FDA approval and provide seven years of market exclusivityCardioMap(R) is intended to provide early, non-invasive testing for heart…

Thursday May 26, 2022 - 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Efforts Boosted by New Study Indicating Effectiveness of Psychedelic Compounds

Recent study indicates psychedelic compounds show significant promise in treating a range of mental-health disordersParticipants given psilocybin therapy reported a rapid, sustained improvement in their depressionCybin’s CYB003 has demonstrated less variability, faster onset, shorter duration and better brain penetration than oral psilocybin A new study sponsored by Imperial College London reports that psychedelic compounds may be effective in treating mental-health disorders (https://ibn.fm/xSdZv). The study supports…

Monday May 16, 2022 - 10:30 am

Aditxt Inc. (NASDAQ: ADTX) Is ‘One to Watch’

Aditxt is commercializing new innovations with focus on mapping and reprogramming the immune systemAditxt is actively adding distribution channel partners for AditxtScore(TM) throughout the U.S. and globallyThe company aims to expand reimbursement coverage for AditxtScore(TM) for COVID-19 from private insurance and public payers while developing and commercializing tests for other indicationsAditxt intends to advance its ADi(TM) therapeutics pipeline into clinical trials in the coming months,…

Wednesday May 11, 2022 - 11:15 am

Silo Pharma Inc. (SILO) Spotlight: Ketamine

Ketamine shows promise in treating Alzheimer’s Disease, Parkinson’s Disease as well as depression, suicide ideation and more In 2021, Silo Pharma (OTCQB: SILO) entered into a joint venture with Zylö Therapeutics to “explore the clinical development of ketamine using ZTI’s Z-pod (transdermal) technology.” This innovative technology allows Silo, an early-stage biopharmaceutical company, to develop a ketamine delivery system for those suffering dysphagia, a difficulty or…

Wednesday May 11, 2022 - 10:30 am

Investor Event Turns Spotlight on Novel Brain Cancer Drug Candidate Global Trial Under Way by CNS Pharmaceuticals, Inc. (NASDAQ: CNSP)

CNS Pharmaceuticals is developing a proprietary drug candidate that has the potential to deliver a novel solution for unmet medical needs in treating an incurable brain cancerCNS’s drug candidate is called Berubicin, a powerful anthracycline that appears to be the first such chemotherapy agent able to successfully cross the blood-brain barrier Berubicin dosing has begun in a potentially pivotal global trial that is recruiting glioblastoma multiforme…

Friday May 06, 2022 - 9:00 am

Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Proprietary CYB003 Set to Move Forward in First-in-Human Phase 1/2a Clinical Trial

Cybin has selected Clinilabs Drug Development Corporation as CRO for its Phase 1/2a clinical trial evaluating CYB003 for treating major depressive disorder (“MDD”)MDD impacts more than 264 million people worldwide, is a leading cause of mental disability worldwidePreclinical studies show CYB003 may have significant advantages over classic psilocybin In a significant step forward in the study of alternative treatments for major depressive disorder, Cybin (NEO:…

Thursday Apr 28, 2022 - 9:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Preclinical Data from CYB004 Study Showing Significant Advantages

Earlier studies show that CYB004 via inhalation may solve existing challenges and support a clinical path forward for this important therapeuticCybin is currently developing CYB004 for the treatment of anxiety disordersThe new chemical entity is covered by a patent issued earlier this year Cybin (NEO: CYBN) (NYSE American: CYBN) has released data from a pharmacokinetic study focused on evaluating CYB004, the company’s proprietary deuterated dimethyltryptamine (“DMT”)…

Monday Apr 18, 2022 - 9:30 am

Mullen Automotive Inc. (NASDAQ: MULN) Named EV Startup to ‘Watch Out For’ by Leading Auto Site

Mullen called “dark horse” in HotCars 2022 list of top EV startupsOther online articles also shining spotlight on what CarBuzz calls “the real deal” Mullen CEO calls FIVE model “just the start” Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, is starting the new year with a bang: the company is ranked no. 2 on the HotCars 2022 list of top-10 EV startups (https://ibn.fm/Gb5IR).…

Monday Apr 18, 2022 - 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CYB004 Pipeline Program Receives Key Patent Approval from WIPO

World Intellectual Property Organization has published CYBN’s international patent applicationPublication of patent application demonstrates CYBN’s continued commitment to discovering, developing psychedelic-based treatment optionsCompany continues to see strong protection for growing intellectual property portfolio of psychedelic-based compounds Cybin (NEO: CYBN) (NYSE American: CYBN) announced that the World Intellectual Property Organization (“WIPO”) has published an international patent application filed by Cybin. According to Cybin, the application, titled "Methods…

Wednesday Apr 13, 2022 - 9:00 am

European Regulatory Approvals Help CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Advance ‘Potentially Pivotal’ Study of Novel Brain Cancer Drug

Novel brain cancer drug developer CNS Pharmaceuticals is developing a proprietary pharmaceutical candidate called Berubicin for the treatment of glioblastoma multiforme (“GBM”)CNS has received Fast Track designation for Berubicin, which will allow the company more frequent communications with the FDA CNS has initiated a global potentially pivotal clinical trial to evaluate Berubicin in treating GBM and began dosing patients at sites scattered across several states last…

Tuesday Apr 12, 2022 - 9:15 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Gaining Advantage on Processing Rare Cannabinoids with the Help of Subsidiary Bay Medica

There is an urgent need for large-scale biosynthetic processing that preserves the purity and consistency of cannabinoidsAcquired by InMed in October 2021, Bay Medica is a private U.S. firm specializing in the manufacturing and commercialization of rare cannabinoids for the health and wellness sectorInMed has two cannabinol formulations currently in development for ocular and dermatological diseases – INM-088 (ocular for glaucoma) and INM-755 (dermatological cream…

Tuesday Apr 12, 2022 - 9:00 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Provides Business Update, Marking 2021 Achievements

In 2021, Mydecine made significant progress in creating and commercializing new treatments for mental health and addiction disordersIt also made a noteworthy shift in focus to reducing expenses and increasing efficiencies for continued clinical trials and the expansion of its IP portfolioFor 2022, the company plans to build on the progress achieved in 2021With new additions to its board, its conditional IRB approval, and the…

Monday Apr 11, 2022 - 9:00 am

Silo Pharma Inc. (SILO) Emerging Leader as Psychedelics ‘on the Cusp of Entering Mainstream Psychiatry’

Mainstream acceptance of psychedelics took a “significant leap forward” with study results published in “Nature Medicine”Many say it is only a matter of time before FDA grants approval for psychoactive compounds to be used therapeuticallySILO is focused on merging traditional therapeutics with psychedelic research for people suffering from underserved indications “The Psychedelic Revolution Is Coming,” proclaims a “New York Times” article, which notes that as…

Monday Apr 11, 2022 - 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Leading the Charge toward Advancing Research on Treatments for Primary and Metastatic Central Nervous System Cancers

CNS Pharmaceuticals is a clinical stage biotechnology company focused on the development of novel treatments for brain tumorsThe company’s lead product candidate, Berubicin, is a novel anthracycline that is designed to cross the blood-brain barrierThe blood-brain barrier ordinarily hinders the vascular delivery of therapeutic substances to brain tumorsBy crossing this protective barrier, Berubicin holds promise for the thousands of adult Americans diagnosed with malignant central…

Friday Apr 08, 2022 - 9:15 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Strengthening Foothold in Multibillion-Dollar Mental Health Space

Recent study forecasts global mental health market to reach almost $538B by 2030One in five people in the United States deals with mental illness, including depression, anxiety, PTSD and moreCybin is moving three drug candidates forward, targeting major depressive, alcohol use and anxiety disorders A recent market study reports that the global mental health market, which was valued at $383.31 billion in 2020, is estimated…

Wednesday Apr 06, 2022 - 9:00 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Increasing Rare Cannabidiol Product Portfolio, Revenues

InMed Pharmaceuticals is a Canadian clinical-stage drug development company focused on the development of rare cannabinoids and their synthetic counterpoints for B2B sales and pharmaceutical potentialInMed expects to have rare cannabinoids CBDV and THCV available for B2B sale to the health and wellness market in the coming months, following on the heels of its CBC and CBT productsThe company recently reported its first revenues from…

Tuesday Apr 05, 2022 - 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Begins Recruitment for Study Measuring Ketamine’s Psychedelic Effect

Cybin-sponsored study will use Kernel Flow, Kernel’s quantitative neuroimaging.Company hopes to learn more about impact ketamine has on brain activity, overall mental well-being.Study results may lead to future studies supporting CYBN’s mission to develop psychedelics into therapeutics. Cybin’s (NEO: CYBN) (NYSE American: CYBN) efforts to transform the mental-health treatment landscape have reached a key milestone: the company is actively recruiting participants for its upcoming feasibility study…

Articles

Articles Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions